Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLC

Zaiwen Fan

Status and phase: Unknown; Phase 3

Conditions: Advanced Cancer; Lung Cancer, Nonsmall Cell

Treatments: Drug: EGFR-TK Inhibitor

Study type: Interventional

Funder types: Other

Identifiers

NCT03008109

AirFGH

Details and patient eligibility

About

EGFR Tyrosine-Kinase Inhibitor monotherapy is widely used in treatment of patients with EGFR mutation-positive Non-small cell lung cancer(NSCLC), In despite of the benefit of PFS （progression-free survival） , the OS （ overall survival） is limited extended. This study is aim to observe the safety and efficacy of the combination of an anti-angiogenic drug recombinant human-endostatin with EGFR TKI ,to find out a new strategy which may further extend the PFS and OS with a tolerated toxicity.

Enrollment: 80 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Advanced NSCLC,EGFR mutation positive,PS（performance status） 0-2,Patients were required to have one or more measurable lesions

Exclusion criteria

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

80 participants in 1 patient group

EGFR-TK inhibitor plus RH-endostatin

Experimental group

Description:

EGFR-TKI icotinib:125mg Tid RH-endostatin:15mg/m2 ,d1-7

Treatment:

Drug: EGFR-TK Inhibitor